Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival

• Published in: Proteomics (Weinheim) Vol. 6; no. 11; pp. 3466 - 3476
• Main Authors: Kim, Hyunki, Kang, Hyun Ju, You, Kwon Tae, Kim, Se Hoon, Lee, Kang Young, Kim, Tae Il, Kim, Chul, Song, Si Young, Kim, Hye-Jung, Lee, Cheolju, Kim, Hoguen
• Format: Journal Article
• Language: English
• Published: Weinheim WILEY-VCH Verlag 01.06.2006; WILEY‐VCH Verlag; Wiley-VCH
• Subjects: Adenoma - diagnosis; Adenoma - metabolism; Adenoma - pathology; Analytical, structural and metabolic biochemistry; Biological and medical sciences; Biomarker; Biomarkers, Tumor - metabolism; Carcinoma - diagnosis; Carcinoma - metabolism; Carcinoma - pathology; Colon - metabolism; Colon - pathology; Colorectal carcinoma; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - metabolism; Colorectal Neoplasms - pathology; Down-Regulation; Electrophoresis, Gel, Two-Dimensional; Fundamental and applied biological sciences. Psychology; Humans; Intestinal Mucosa - metabolism; Intestinal Mucosa - pathology; Miscellaneous; Prognosis; Proteins; Proteome - metabolism; Selenium-binding protein 1; Selenium-Binding Proteins - metabolism; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Array Analysis; Human; orectal carcinoma / Prognosis / Selenium-binding protein 1; Binding protein; Biomarker; Suppression; Proteomics; Carcinogenesis
• ISSN: 1615-9853; 1615-9861
• DOI: 10.1002/pmic.200500629

The purpose of this study was to analyze altered protein expression in cancer tissues and determine its relationship to prognosis in colorectal carcinomas. We performed proteomic expression analysis on 14 colorectal carcinomas and matched nontumorous colonic mucosa by 2‐DE and MALDI‐TOF‐MS. Comparative analysis of the respective spot patterns on 2‐DE showed 14 spots that were markedly changed in the colorectal carcinomas. Among them, selenium‐binding protein 1 (SELENBP1) was markedly decreased in 12 (85%) carcinomas. The reduced expression of SELENBP1 was further supported by Western blot analysis and immunohistochemistry. Suppression of SELENBP1 was further analyzed in another eight‐paired adenomas and carcinomas from the same patients using Western blot analysis and immunohistochemistry, and revealed that one adenoma and seven carcinomas exhibited markedly reduced SELENBP1 expression. Patients with low levels of SELENBP1 expression had significantly lower overall survival rates (72 vs. 85%, p = 0.021) among the 240 stages II and III colorectal carcinomas by using tissue microarray analysis. Our findings indicate that suppression of SELENBP1 is a frequent and late event in colorectal carcinogenesis, and may contribute to the rapid progression of colorectal carcinoma.